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Abstract
Background and objectives Neurocognitive problems in CKD are well documented; time-efficient methods are
needed to assess neurocognition in this population. We performed the first study of the efficient 1-hour Penn
Computerized Neurocognitive Battery (CNB) in children and young adults with CKD.
Design, setting, participants, & measurementsWe administered the Penn CNB cross-sectionally to individuals
aged 8–25 yearswith stage 2–5CKD (n=92, enrolled from three academic nephrology practices from2011 to 2014)
and matched healthy controls (n=69). We analyzed results from 12 tests in four domains: executive control,
episodic memory, complex cognition, and social cognition. All tests measure accuracy and speed; we converted
raw scores to age-specific z-scores on the basis of Philadelphia Neurodevelopmental Cohort (n=1790) norms.
We analyzed each test in a linear regressionwith accuracy and speed z-scores as dependent variables andwith (1)
CKD versus control or (2) eGFR as explanatory variables, adjusted for race, sex, and maternal education.
Results Patients with CKD (mean6SD eGFR, 48625 ml/min per 1.73 m2; mean age, 16.363.9 years) and controls
(mean eGFR, 98620 ml/min per 1.73 m2; mean age, 16.064.0 years) were similar demographically. CKD
participants had lower accuracy than controls in tests of complex cognition, with moderate to large effect sizes:
20.53 (95% confidence interval [95%CI],20.87 to20.19) for verbal reasoning,20.52 (95%CI,20.83 to20.22) for
nonverbal reasoning, and 20.64 (95% CI, 20.99 to 20.29) for spatial processing. For attention, patients with
CKD had lower accuracy (effect size, 20.35 [95% CI,20.67 to 20.03]) but faster response times (effect size, 0.44
[95% CI, 0.04 to 0.83]) than controls, perhaps reflecting greater impulsivity. Lower eGFR was associated with
lower accuracy for complex cognition, facial and visual memory, and emotion identification tests.
Conclusions CKD is associated with lower accuracy in tests of complex cognition, attention, memory, and
emotion identification, which related to eGFR. These findings are consistent with traditional neurocognitive
testing in previous studies.
Clin J Am Soc Nephrol 11: 39–46, 2016. doi: 10.2215/CJN.02110215
Introduction
Neurocognitive problems have been well documented
in children and adults with CKD. Children with CKD
show impairments in attention, memory, executive
functioning, language, visual-spatial abilities, and
academic achievement (1–4), while adults with CKD
have increased risk of cognitive impairment and de-
mentia (5–9). Impaired cognitive function has been
linked to poor treatment adherence in multiple dis-
ease states, including kidney transplantation (10–13).
Improved characterization of cognitive dysfunction in
children and adults with CKD could therefore allow
clinicians to implement targeted interventions
(1,14,15) and provide more effective patient commu-
nication to promote adherence. A significant barrier to
increased neurodevelopmental surveillance of
patients with CKD, however, is the costly and time-
intensive nature of traditional neurocognitive test bat-
teries. Neuropsychological evaluations are often not
completed in tandem with clinical care visits, which
further limits the utility of cognitive assessment of
changes related to disease status.
The Penn Computerized Neurocognitive Battery
(CNB) was developed to provide an efficient method
to assess performance in a range of cognitive domains
linked to specific brain systems (16). The Penn CNB
takes an average of 1 hour to complete and provides
measures of accuracy and speed in tests spanning five
areas of neurobehavioral function: executive control,
episodic memory, complex cognition, social cognition,
and sensorimotor speed. Results from the Penn CNB
were similar to those of traditional neuropsychological
testing in a healthy normative sample (17) and in adult
patients with schizophrenia (18). The Penn CNB was
also applied in the Philadelphia Neurodevelopmental
Cohort (PNC), a large-scale community genomic study
of brain development, which generated normative data
in children and young adults aged 8–21 years (19).
To our knowledge, the current study is the first
systematic investigation of the Penn CNB in children
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and young adults with CKD. The goal of this study was to
use the Penn CNB to characterize neurocognitive function
in children and young adults with CKD and in healthy
controls. We also sought to examine whether findings in
the Penn CNB are similar to those from previous studies
that used traditional neurocognitive testing in children and
young adults with CKD. We hypothesized that the Penn
CNB would reveal deficits in domains similar to those
identified in previous studies, including language, visual-
spatial ability, memory, and executive functioning (1,4).
Materials and Methods
The Penn CNB was investigated within the Neurocog-
nitive Assessment and Magnetic Resonance Imaging Anal-
ysis of Children and Young Adults with Chronic Kidney
Disease (NiCK) Study. The NiCK study is a cross-sectional
investigation of children and young adults, aged 8–25
years, with stage 2–5 CKD (eGFR,90 ml/min per 1.73 m2,
including dialysis and post-transplant) compared with
healthy controls matched on age, sex, and socioeconomic
status (using insurance status as a proxy). Complete in-
clusion and exclusion criteria for the NiCK Study have
been published elsewhere (20). Eligible patients with
CKD were identified by manual review of medical records
of patients who were scheduled to be seen in nephrology
clinics at the Children’s Hospital of Philadelphia (CHOP),
the Hospital of the University of Pennsylvania, and the
Nemours Hospital for Children during the recruitment
period (August 2011–October 2014); patients were invited
to participate at their regular nephrology clinic visits.
Healthy controls were identified from CHOP general
practice locations and were invited to participate in the
study via mail. Those who were interested in participating
contacted the study coordinator at CHOP to be screened
and enrolled. Patients with comorbidities that indepen-
dently affect brain function (e.g., seizure disorder, trau-
matic brain injury, genetic syndromes) or the ability to
complete test measures (profound developmental disabil-
ities) were excluded from participating to ensure that
study results reflect the effects of kidney disease. The in-
stitutional review board of the Children’s Hospital of Phil-
adelphia approved the study, and the study adhered to
the Declaration of Helsinki. All participants and/or
guardians provided written informed consent.
The Penn CNB includes 14 tests assessing five neuro-
behavioral functions: executive control, episodic memory,
complex cognition, social cognition, and praxis speed.
Except for praxis speed (results of which were not analyzed
for the current study), all tests measure both accuracy
(number of correct responses) and speed (response time for
correct items).
For the current analysis, raw scores for accuracy and
speed for each test were converted to age-specific z-scores
based on the performance of a cohort of 1790 typically
developing healthy children and young adults selected
from the larger PNC study (19). From this cohort, scores
were collapsed in 2-year intervals to form the basis for the
development of the z-scores. We selected 2-year intervals
to ensure adequate numbers of participants within each
age interval and to minimize the effect of normal variabil-
ity in the rate of development of neurocognitive skills (21).
For ease of interpretation, z-scores were calculated such
that higher z-scores always reflect better performance (i.e.,
higher accuracy and shorter response times correspond to
higher z-scores).
To assess the neurocognitive effects of CKD, we per-
formed linear regression analysis, with z-scores for accu-
racy and speed for each test as the dependent variables
and either (1) diagnostic group (CKD versus healthy con-
trol) or (2) eGFR as the explanatory variables. Analyses
were adjusted for race (black versus nonblack race), sex,
and maternal education (in years). To examine whether
inclusion of transplant recipients in the CKD group af-
fected our results, we also performed a sensitivity analysis
comparing the CKD and control groups after excluding
transplant recipients.
The performance of CKD participants was compared
with that of a concurrently recruited cohort of healthy
control participants in order to minimize confounding due
to differences in test administration (e.g., environment,
staff, and timing) between NiCK study participants and
the historical PNC cohort.
Clinical and demographic characteristics were compared
between the CKD and control groups using the Wilcoxon
rank sum test for continuous variables, the Fisher exact test
for categorical variables, and the Kruskal-Wallis test for
ordinal variables.
As a secondary analysis, we also compared Penn CNB
performance for CKD participants with that of the refer-
ence population of 1790 healthy individuals from the PNC
study. Wilcoxon signed-rank tests were performed to
determine whether observed median age-specific z-scores
for accuracy and speed in each subtest for the CKD group
significantly differed from the expected median z-scores of 0.
Data were analyzed using R software, version 3.1.0
(R Foundation for Statistical Computing, www.R-project.
org). The significance level for all data analyses was set
at P=0.05 (two-sided).
Results
Clinical and Demographic Characteristics
Penn CNB results were analyzed for 92 patients with
CKD and 69 controls. Clinical and demographic charac-
teristics of patients with CKD and controls are shown in
Table 1. CKD and control participants were of similar age.
Slightly higher proportions of patients with CKD were
male, of Hispanic ethnicity, and from households with in-
come ,$30,000/year, but these differences were not sta-
tistically significant. A higher proportion of control
participants was black, but this difference was also not
statistically significant. Level of maternal education was
slightly higher in the control group than in the CKD group
(14.7 versus 13.6 years; P=0.03). As expected, patients with
CKD had lower mean eGFR than controls (48 versus
98 ml/min per 1.73 m2; P,0.001). One quarter of patients
with CKD had functioning transplants and 3% were re-
ceiving dialysis at the time of their study visit.
Group Comparisons of Patients with CKD versus Controls
As a group, patients with CKD showed significantly lower
accuracy scores than controls in tests assessing complex
cognition, with moderate to large effect sizes: 20.53 (95%
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confidence interval [95% CI], 20.87 to 20.19) for verbal
reasoning (P=0.002), 20.52 (95% CI, 20.83 to 20.22) for
nonverbal reasoning (P=0.001), and 20.64 (95% CI, 20.99
to 20.29) for spatial processing (P,0.001). Accuracy scores
for attention were also lower in patients with CKD than
controls (effect size, 20.35 [95% CI, 20.67 to 20.03];
P=0.03). There were no statistically significant differences
in group comparisons between patients with CKD and con-
trols in accuracy scores for tests assessing other domains of
executive control (abstraction/mental flexibility and work-
ing memory). In addition, group comparisons between
patients with CKD and controls did not detect any statis-
tically significant differences in accuracy scores for tests
assessing episodic memory or social cognition (Table 2).
Comparison of speed scores between patients with CKD
and controls revealed only one test with a statistically
significant group difference in performance: Patients with
CKD had higher speed scores (i.e., faster responses for cor-
rect items) than control participants for attention (effect
size, 0.44 [95% CI, 0.04 to 0.83]; P=0.03) (Table 2).
Sensitivity analysis excluding kidney transplant recipi-
ents from the CKD group yielded similar results (results
not shown).
Relationship of Penn CNB Results with eGFR
In analyses using eGFR as a continuous explanatory
variable, higher eGFR was associated with higher accuracy
performance on all three subtests assessing the domains of
complex cognition: For every 10–ml/min per 1.73 m2
higher eGFR, accuracy z-score for verbal reasoning was
higher by 0.09 (95% CI, 0.04 to 0.14; P=0.001 for regres-
sion); for nonverbal reasoning, it was higher by 0.06 (95%
CI, 0.02 to 0.11; P=0.01); and for spatial processing, it was
higher by 0.10 (95% CI, 0.05 to 0.16; P,0.001) (Figure 1A).
In addition, higher eGFR was associated with higher
accuracy in two of the three memory domains: For every
10–ml/min per 1.73 m2 higher eGFR, accuracy z-score for
facial memory was higher by 0.06 (95% CI, 0.01–0.12;
P=0.02) and for spatial memory was higher by 0.08 (95% CI,
0.03 to 0.14; P=0.004). Higher eGFR was also associated
with higher accuracy performance in emotion identifica-
tion, one of the three subtests comprising social cognition:
For every 10–ml/min per 1.73 m2 higher eGFR, z-score was
higher by 0.07 (95% CI, 0.02 to 0.13; P=0.01). There were no
significant relationships between eGFR and accuracy per-
formance in executive control, verbal memory, or the other
domains of social cognition (Figure 1A). There were no
statistically significant associations between eGFR and
speed performance in any domains (Figure 1B).
Comparison of Patients with CKD versus Reference
Population from PNC Study
Median z-scores for accuracy and speed in each Penn
CNB subtest for participants with CKD are shown in Sup-
plemental Table 1. Similar to our findings in the group
comparisons described in the preceding section, accuracy
z-scores for patients with CKD were lowest in tests assess-
ing complex cognition. These scores differed from the ex-
pected z-score of 0 from the PNC study reference
population with a high degree of statistical significance.
Median z-scores for patients with CKD were 20.49 for
verbal reasoning (Wilcoxon 95% CI, 20.83 to 20.37
[P,0.001] for difference from PNC population), 20.54
for nonverbal reasoning (Wilcoxon 95% CI, 20.69 to
20.28; P,0.001), and 20.45 for spatial processing (Wil-
coxon 95% CI, 20.60 to 20.16; P=0.001). Patients with
CKD also had lower median accuracy z-scores than the
reference population in several other subtests, albeit with
somewhat smaller effect sizes. These included tests assess-
ing episodic memory (20.21 for verbal memory [Wilcoxon
95% CI, 20.62 to 20.04; P=0.01], 20.40 for facial memory
[Wilcoxon 95% CI, 20.64 to 20.13; P=0.004], and 20.30 for
spatial memory [Wilcoxon 95% CI, 20.53 to 20.05;
P=0.02]), one subtest of social cognition (20.34 for age
differentiation [Wilcoxon 95% CI, 20.59 to 20.13;
P=0.01]), and two subtests of executive control (20.24 for
abstraction/mental flexibility [Wilcoxon 95% CI, 20.48 to
-20.04; P=0.03] and 20.04 for working memory [Wilcoxon
95% CI, 20.52 to 20.09; P=0.01]) (Supplemental Table 1).
Comparison of speed z-scores for patients with CKD
with the PNC study reference population showed that
patients with CKD had lower median speed z-scores for
attention (20.33 [Wilcoxon 95% CI, 20.65 to 20.20;
P,0.001]) and emotion identification (20.17 [Wilcoxon
Table 1. Clinical and demographic characteristics of patients with CKD and controls
Characteristic CKD (n=92) Control (n=69) P Value
Age, yr 16.363.9 16.064.0 0.64
Male participants 65 55 0.20
Black 27 38 0.17
Hispanic 10 7 0.78
Income 0.44
,$30,000/yr 35 26
.$75,000/yr 37 39
Maternal education, yr 13.662.7 14.762.9 0.03
eGFR, ml/min per 1.73 m2 47.9624.5 97.9620.1 ,0.001
Current dialysis 3 – –
Functioning transplant 26 – –
Data shown as mean6SD or proportion (%). eGFR calculated with bedside Chronic Kidney Disease in Children equation (32) for
participants aged ,18 years or the Modification of Diet in Renal Disease equation (33) for those $18 years. eGFR for participants on
dialysis was defined as 10 ml/min per 1.73 m2.
Clin J Am Soc Nephrol 11: 39–46, January, 2016 Computerized Neurocognitive Battery in CKD, Hartung et al. 41
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42 Clinical Journal of the American Society of Nephrology
95% CI, 20.42 to 20.06; P=0.01]) but had higher speed
z-scores for nonverbal reasoning (0.47 [Wilcoxon 95% CI,
0.18 to 0.50; P,0.001]) (Supplemental Table 1).
Discussion
Neurocognitive dysfunction is an important conse-
quence of CKD and can have far-reaching social, economic,
and health effects. On an individual level, neurocognitive
impairment affects school performance (22,23), employ-
ment (24,25), and health care self-management (13), par-
ticularly when complex medical regimens are prescribed
(26). From a societal perspective, this translates to in-
creased burden on school and health systems and health
insurance programs. Despite the importance of neurocog-
nitive dysfunction in CKD, measuring these deficits in
clinical research settings can be difficult given the cost
and availability of traditional neurocognitive testing. We
therefore sought to evaluate the use of a computerized
testing method, the Penn CNB, in children and young
adults with CKD.
In this study, we compared Penn CNB performance of
children and youth with CKD with that of concurrently
recruited health controls matched for age and socioeco-
nomic status in the NiCK study. In addition, because of the
wide range of eGFRs within our CKD cohort, we also
examined the relationship between Penn CNB performance
and eGFR. We found that patients with CKD as a group
had significantly lower accuracy performance than controls
in all three subtests of complex cognition (verbal and
nonverbal reasoning and spatial processing). Group com-
parisons also revealed lower accuracy performance for
Figure 1. | Differences in z-scores for accuracy and speed per 10–ml/min per 1.73 m2 higher eGFR for each Penn Computerized Neuro-
cognitive Battery subtest. Point estimates and 95% confidence intervals (error bars) for z-score differences are shown, adjusted for race, sex,
and maternal education. (A) Accuracy. (B) Speed. ADT, Age Differentiation Test; CPF, Penn Face Memory; CPW, Penn Word Memory; ER40,
Penn Emotion Identification Test; MEDF, Penn Emotion Differentiation Test; PCET, Penn Conditional Exclusion Test; PCPT, Penn Continuous
Performance Test; PLOT, Penn Line Orientation Test; PMAT, PennMatrix Reasoning Test; PVRT, Penn Verbal Reasoning Test; SLNB, Short Letter
N-Back Test; VOLT, Visual Object Learning Test.
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attention in the patients with CKD. Notably, however,
patients with CKD had faster response times than controls
in the test for attention. This trade-off of accuracy for speed
was found in a prior study of the Penn CNB evaluating age-
and sex-related differences in performance (22). In that
study of individuals aged 8–21 years, male participants
were faster but less accurate than female participants in
the test of attention, a finding attributed to greater impul-
sivity in males (22,27). Although our CKD sample did
have a slightly higher proportion of male participants
compared with the control group (Table 1), our analyses
were adjusted for sex, suggesting a CKD-specific effect on
impulsivity.
In a separate regression analysis, we found that lower
eGFR was associated with lower accuracy performance in
complex cognition, facial memory, spatial memory, and
emotion identification.
As a secondary analysis, we also compared the perfor-
mance of patients with CKD in the Penn CNB with that of a
reference population of healthy children and young adults
in the PNC study. Similar to our comparisons with the
concurrent NiCK study control group, these analyses
showed that patients with CKD had significantly lower
than expected accuracy performance in tests of complex
cognition. Patients with CKD also had lower than expected
accuracy performance in tests of episodic memory, exec-
utive control, and social cognition.
Previous studies in children with CKD using traditional
testing methods have demonstrated deficits in attention,
memory, executive functioning, language, visual-spatial
abilities, and academic achievement (1–4). The pattern of
the findings uncovered using the Penn CNB in the current
study show significant overlap with previous studies.
However, the association between lower eGFR and lower
accuracy in emotion identification is a relatively novel
finding that adds to the knowledge base about the neuro-
cognitive profile of CKD and may strengthen the utility of
the Penn CNB. Measures of social cognition are not widely
used in traditional neurocognitive testing, which may con-
tribute to under-recognition of these deficits. One prior
study in pediatric kidney transplant recipients demon-
strated impairment in recognizing emotional states (14).
A recent study in adult kidney transplant patients re-
vealed that alexithymia (the inability to recognize and
express emotions) is positively correlated with noncompli-
ance (28), underscoring the importance of recognizing def-
icits in social cognition. These findings support further
investigation and validation of the Penn CNB in CKD
populations.
The Penn CNB is a cognitive neuroscience–based assess-
ment that was developed on the basis of tasks shown ex-
perimentally to map to specific brain systems with
functional neuroimaging studies (16) (available for down-
load by investigators at http://www.med.upenn.edu/bbl).
The domains showing decreased Penn CNB performance in
CKD in our study are expected to map to several functional
areas: bilateral temporo-parietal regions (complex cogni-
tion), frontal and bilateral anterior medial temporal lobes
(episodic memory), frontal-parietal network (attention),
and temporo-limbic regions (emotion identification) (16).
The mechanisms by which CKD leads to neurocognitive
alterations are poorly understood but are likely related to
both metabolic derangements (29) and subclinical vascular
disease (30). Ongoing analysis of findings from multimodal
magnetic resonance imaging performed in the NiCK study
will help to identify any regional changes in brain struc-
ture, functional connectivity, and cerebral blood flow asso-
ciated with CKD and will help to shed further light on the
neuropathology associated with CKD (20).
Strengths of this study include the direct comparison of
neurocognitive performance of patients with CKD with
that of a concurrently recruited cohort of healthy controls
matched for age and socioeconomic status, rather than
solely with historical controls or population-based norma-
tive samples. This decreases the potential for variability in
neurocognitive performance arising from different testing
conditions or other environmental factors. Although we
consider our primary analysis to be the more rigorous one
for this reason, our secondary analysis comparing our CKD
group to the larger PNC study reference population
strengthens our findings. In both analyses, participants
with CKD had significantly lower accuracy in all three
subtests of complex cognition (verbal and nonverbal
reasoning and spatial processing).
Some demographic variables differed between the CKD
and control groups, but our statistical analyses controlled
for these by adjusting for important covariates, such as
maternal education, race, and sex. However, we cannot
exclude the effects of other unmeasured confounders on
our results. Unmeasured confounders may also have
affected our comparisons with the historical PNC reference
population. Another potential limitation is the heteroge-
neity of our CKD group, which had a wide range of kidney
function and also included post-transplant participants.
However, sensitivity analysis excluding transplant recip-
ients from the CKD group yielded similar results. Another
potential limitation to our study is its cross-sectional
nature. Although we found that lower eGFR was associ-
ated with lower performance in certain neurocognitive
domains, a cross-sectional study does not allow us to
determine whether this relationship is causal. Although we
performed multiple analyses, here we report significant
findings using P,0.05. However, the group differences be-
tween CKD and control participants in complex cognition per-
formance in both our primary and secondary analyses were
significant enough that they would have survived even the
conservative Bonferroni correction (a=0.05/12=0.004).
The Penn CNB offers an efficient method for neuro-
cognitive assessment of children and young adults with
CKD. As a novel approach to assessing neurocognitive
function, the Penn CNB demonstrates findings consistent
with prior reports of poorer performance using traditional
neurocognitive batteries in children with CKD. The Penn
CNB’s ease of administration and the shortened time
needed compare favorably to administration of a tradi-
tional neurocognitive battery. The Penn CNB may there-
fore facilitate increased collection of standardized
neurocognitive data in a wider variety of clinical research
settings and could allow further exploration of risk factors
for cognitive dysfunction in CKD. A better understanding
of neurocognitive functioning in dysfunction in patients
with CKD may have important implications for how we
communicate health care information, promote adherence,
and tailor treatment plans as disease progresses.
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